Meeting
2012 ASCO Annual Meeting
Phase I trial of temsirolimus (TEM), irinotecan (IRN), and temozolomide (TMZ) in children with refractory solid tumors: A Children's Oncology Group study.
Authors
Rochelle Bagatell
The Children's Hospital of Philadelphia, Philadelphia, PA
Rochelle Bagatell , Robin Elizabeth Norris , Ashish M Ingle , Charlotte H Ahern , Jennifer Saggio , Anthony Little , Brenda Weigel , Susan Blaney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT01141244
Citation
J Clin Oncol 30, 2012 (suppl; abstr 9540)
DOI
10.1200/jco.2012.30.15_suppl.9540
Abstract #
9540
Poster Bd #
20
Abstract Disclosures
Similar Posters
First Author: Stuart Cramer
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster
Poster
2013 ASCO Annual Meeting
A phase I trial and pharmacokinetic study of trebananib (AMG386) in children with recurrent or refractory solid tumors: A Children’s Oncology Group Phase 1 Consortium report.
First Author: Sarah Leary
Poster
2011 ASCO Annual Meeting
A pediatric phase I trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: A Children's Oncology Group Phase I Consortium Study.
First Author: T. R. Hummel